Objectives: Ceftaroline, approved in Europe in 2012, has activity against methicillin-resistant Staphylococcus aureus (MRSA), with MIC 90 values of 1 -2 mg/L depending on geographical location. During a global 2010 surveillance programme, conducted prior to the European launch, 4 S. aureus isolates, out of 8037 tested, possessing ceftaroline MIC values of .2 mg/L were identified. The objective of this study was to characterize these four isolates to elucidate the mechanism of ceftaroline resistance.
Introduction
The increasing level of resistance to multiple classes of antibacterial agents coupled with the paucity of new agents in clinical development has caused worldwide concern regarding the spread of multidrug-resistant bacterial pathogens causing serious infections that are unable to be adequately treated. Methicillinresistant Staphylococcus aureus (MRSA) still represents a significant cause of healthcare-associated infections and the increased prevalence of community-associated MRSA infections is of particular concern. Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a new cephalosporin that was approved in Europe in 2012 for the treatment of community-acquired pneumonia and complicated skin and soft tissue infections. It was approved in the USA in 2010 for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. 1 Ceftaroline has excellent in vitro activity against Streptococcus spp., but the distinguishing feature from the majority of other b-lactam antibacterial agents is the activity against MRSA. 2 The anti-MRSA activity of ceftaroline is due to its increased affinity for penicillin-binding protein (PBP) 2a (MecA), 3 the PBP that is acquired through the horizontal acquisition of the staphylococcal cassette chromosome mec (SCCmec) in multiple epidemiological lineages of S. aureus and confers resistance to other b-lactam antibiotics. 4, 5 However, multiple genes have been implicated in the maximal expression of methicillin and b-lactam resistance in S. aureus. 6 -8 These include the four PBPs (PBP1 -4) as well as PBP2a. Further, the absolute level of resistance also is dependent on other chromosomally encoded factors that are involved in cell wall precursor formation and turnover. These include the fem-encoded proteins (factors essential for methicillin resistance), including FemA and FemB, involved in the correct formation of the peptidoglycan pentaglycine interpeptide bridge, as well as GlnR (FemC) and GlmM (FemD) involved in glutamine and glucosamine metabolism. In addition, there are three further genes (fmhA, fmhB and fmhC) that encode proteins with significant identity to FemA and FemB that are involved in the formation of the peptidoglycan pentaglycine interpeptide. 8, 9 Previously, bacterial typing methods such as multilocus sequencing typing (MLST) have provided a means to track the evolution and spread of bacterial pathogens such as S. aureus. However, the rapid progression of next-generation sequencing technologies now enables a significantly higher level of discriminatory power and this has been used successfully to establish the evolutionary spread of MRSA lineages. 10 -12 Although the acquisition and loss of mobile genetic elements in the genomic structure of S. aureus is quite common, the core genome of S. aureus isolates has been found to be relatively stable. However, single nucleotide polymorphisms (SNPs) and other minor variations still develop over time and can be used to accurately link multiple S. aureus isolates involved in infection outbreaks and study transmission dynamics. Indeed, several recent studies have successfully used whole genome sequencing to rapidly monitor such scenarios and suggest that these methods may play an important role in developing valuable approaches to infection control in the future. 13 -15 The microbiological activity of ceftaroline and comparator agents is being monitored and tracked through an ongoing global surveillance programme [Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE)]. The objective of this study was to characterize the clinical MRSA isolates identified from the AWARE programme in 2010 (prior to the launch of ceftaroline fosamil in Europe) that resulted in ceftaroline MIC values of .2 mg/L along with ceftaroline-susceptible S. aureus isolates from the same medical centres to identify the molecular mechanisms of decreased ceftaroline activity.
Materials and methods

Collection of bacterial isolates
The resistant MRSA isolates with ceftaroline MIC values of ≥4 mg/L following CLSI interpretive criteria 16 were obtained from separate patients at medical centres in Bangkok, Thailand (n ¼3) and Madrid, Spain (n ¼1) as part of the 2010 AWARE global surveillance programme. Furthermore, additional ceftaroline-susceptible MRSA and methicillin-susceptible S. aureus (MSSA) isolates (ceftaroline MIC of ≤1 mg/L) from the same medical centres were selected for comparative purposes (Table 1) . MRSA isolates from Bangkok and Madrid with a ceftaroline MIC of 2 mg/L were also included for comparison and would be classified as intermediate following CLSI interpretive criteria 16 and resistant following EUCAST interpretive criteria. 17 The reference S. aureus isolates were obtained from the ATCC (Manassas, VA, USA), the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA, Chantilly, VA, USA) and the University of Chicago (Chicago, IL, USA).
Antimicrobial susceptibility testing
The MIC for each isolate was determined using the broth microdilution method following the guidelines of CLSI document M07-A9. All compounds were tested in accordance with CLSI recommendations. S. aureus ATCC 29213 was used as the quality control isolate. Ceftaroline was obtained from Cerexa, Inc. (Oakland, CA, USA) and all other reference compounds used were obtained from US Pharmacopeial Convention (Rockville, MD, USA).
Whole genome sequencing and analysis
Genomic DNA purified on the Maxwell 16 platform (Promega, Madison, WI, USA) and quantified using the Qubit Fluorometer (Invitrogen Life Technologies, Grand Island, NY, USA) was used as input material for library construction. DNA libraries were prepared using the Nextera library construction protocol (Illumina, San Diego, CA, USA) following the manufacturer's instructions and sequenced on a MiSeq Sequencer (Illumina). For each isolate, 2.5 million 150 bp paired-end sequence reads were de novo assembled and analysed using the CLCBio suite of software tools (Cambridge, MA, USA). The SCCmec types of the MRSA isolates were determined by comparison to reference sequences and confirmed by PCR using type-specific oligonucleotides as previously described. 18 The MLST profiles of the isolates were determined by comparison of the seven allele sequences against the curated public database available at http:// saureus.mlst.net. The CLCBio assemblies were then annotated using Prodigal 19 and orthologous groups were clustered using OrthoMCL. 20 The nucleotide sequence of the shared orthologous genes between all of the isolates, representing the core genomes, were used to build the phylogenetic tree using FastTree. 21 The reference genomes used for this analysis were from the ST239 strains JKD6008 22 and T0131, 23 the ST5 strain N315 24 and eight ST228 isolates from a longitudinal study. 25 
Molecular modelling
The structures of S. aureus PBP2 (PDB:2OLU and 2OLV) and S. aureus PBP2a, in the apo form (PDB:1MWT) and in complex with ceftobiprole (PDB:4DKI), were used to support the structural interpretations. The PBP2a mutations identified in this study were mapped onto the known PBP2a structure using PyMOL (Schrö dinger, www.pymol.org).
Results and discussion
Ceftaroline surveillance against S. aureus
During the 2010 global surveillance programme, a total of 8037 S. aureus isolates were acquired and tested for their susceptibility to ceftaroline. The overall S. aureus MIC 90 was determined to be 1 mg/L, although there appear to be different population distributions between the methicillin-resistant and methicillinsusceptible isolates, with the MSSA isolates all being inhibited by ≤1 mg/L ceftaroline and having an MIC 90 value of 0.25 mg/L ( Figure 1 ). The population distribution of MSSA isolates was identical between the major geographic regions, with both the ceftaroline MIC 50 and MIC 90 values being 0.25 mg/L. However, there was a geographical bias observed with the MRSA isolates where both the MIC 50 and MIC 90 values for the USA were one dilution lower than for the other geographic regions (Figure 1 ). There were four MRSA isolates (0.05%) with a ceftaroline MIC of .2 mg/L (Figure 1 ). Three of these isolates came from a single medical centre in Thailand, whereas the last isolate was isolated in Spain. These four isolates, along with ceftaroline-susceptible MRSA and MSSA as well as MRSA isolates that exhibited ceftaroline MIC values of 2 mg/L isolated from the same medical centres, were further characterized (Table 1) .
Susceptibility profiles
The antimicrobial susceptibility profiles of the S. aureus isolates from Thailand and Spain along with S. aureus reference isolates are shown in Genetic analysis of loci involved in full expression of b-lactam resistance
The genome sequences of the surveillance isolates included in this study were determined and the loci implicated in the full expression of b-lactam resistance were compared with the equivalent proteins from the 11 reference strains. Although some polymorphisms were identified in several of the loci known to be involved in maximal expression of b-lactam resistance, the majority of the amino acid substitutions were not uniquely found in isolates with decreased susceptibility to ceftaroline and were therefore felt unlikely to be directly involved in the observed phenotype. Indeed, the only changes that correlated with the ceftaroline MIC values were located in the mecA gene of the MRSA isolates, which encodes the alternative PBP, PBP2a. Variations in PBP2a have previously been reported in several MRSA isolates from Greece that resulted in ceftaroline MIC values of 2 and 4 mg/L. 26 A summary of the differences in the alignment of the PBP2a proteins is presented in Table 2 . The PBP2a sequences from the eight MRSA reference strains were identical except for a single Gly 246 Glu substitution in strain COL and all of these strains were inhibited by a ceftaroline concentration of 1 mg/L except the MRSA strain Mu3, which displays heterogeneous resistance to vancomycin and produces an antagonistic phenomenon between vancomycin and b-lactam drugs. 27, 28 Furthermore, this Gly 246 Glu Characterization of ceftaroline-non-susceptible S. aureus isolates 2067 JAC substitution was also found in the MRSA strain BAA-39 26 and strain ARC3826, both of which had a ceftaroline MIC of 1 mg/L, suggesting that Gly 246 contributes little, if anything, to the ceftaroline susceptibility. Strain ARC3826 also carries Asn 146 Lys and Asn 204 Lys substitutions and the lack of direct involvement of the Asn 204 residue in reduced ceftaroline susceptibility is also supported by the fact that this substitution was found in strain BAA-39, a representative of the ST239 Hungarian clone 26 ( Table 2) . While the Asn 146 Lys mutation is found in strain ARC3826, which has a ceftaroline MIC of 1 mg/L, several other MRSA isolates with this substitution were identified that exhibited a ceftaroline MIC of 2 mg/L ( Table 2) .
The four surveillance isolates that resulted in ceftaroline MIC values of 8 mg/L all had the same two glutamic acid-to-lysine substitutions: Glu 239 Lys in the non-penicillin-binding or dimerization domain and Glu 447 Lys in the penicillin-binding or transpeptidase domain. Furthermore, the Glu 239 Lys substitution was also present in numerous isolates that had a ceftaroline MIC of 2 mg/L that were isolated from the same medical centres in Spain and Thailand (Table 2) . Taken together, these data suggested that a single substitution at key residues in the non-penicillin-binding domain (nPBD) of PBP2a is sufficient to give a slight elevation in the ceftaroline MIC value and that an additional substitution in the penicillin-binding domain (PBD)
gives rise to a further elevation in the ceftaroline MIC value. Of the six MRSA isolates from Thailand that exhibited a ceftaroline MIC of 2 mg/L, three of them carried the Glu 239 Lys substitution in PBP2a, whereas the remaining three isolates carried the Asn 146 Lys substitution. In addition, four of the five MRSA isolates from Spain carried the Glu 239 Lys substitution in PBP2a, whereas one possessed the Asn 146 Lys substitution (Table 2 ).
Epidemiological linkage between isolates
A comparison of the strains' relatedness was performed using MLST analysis. All of the four ceftaroline-resistant isolates with MIC values of 8 mg/L, irrespective of their geographical origin, as well as three of the isolates from Thailand and all five of the isolates from Spain with a ceftaroline MIC of 2 mg/L belonged to ST228 (Table 2 ). In addition, all of these isolates contained the type I SCCmec, giving the designation ST228-MRSA-I (Table 2) . S. aureus isolates with the ST228 allelic profile, also known as the 'Southern German clone', are disseminated throughout Western Europe and are commonly isolated in Spain. 29 However, ST228 isolates have not been isolated in Thailand (according to the MLST database http://saureus.mlst.net), where 'Brazilian' ST239 SCCmec III isolates predominate and contain only one MLST allele in common. 30 -32 Indeed, strain ARC3826 from the same medical Alm et al.
centre in Thailand that had a ceftaroline MIC of 1 mg/L was confirmed to be ST239-MRSA-III ( Table 2 ). The remaining three isolates from Thailand that exhibited a ceftaroline MIC value of 2 mg/L belonged to ST764, which carry four MLST alleles in common with ST228 but have not been reported outside of Japan.
The de novo-assembled genome sequences of the ST228 MRSA isolates from this study were analysed to identify SNPs as well as insertions and deletions and compared with the full genome sequences of eight ST228-MRSA-I isolated from Switzerland over several years. 25 While all the ST228-MRSA-I isolates were closely related, the higher resolution of whole genome SNP analysis on the core orthologous genomes allowed them to be easily differentiated and the ST228-MRSA-I isolates from Spain and Thailand with the Glu 239 Lys variation clearly belonged to a distinct lineage. A hierarchical clustering tree based on the nucleotide sequences of core genomes of the isolates showed that while all the ST228 isolates are related, they can be clearly differentiated into two clades ( Figure 2 ). As expected, ARC3826 clusters closely with the ST239 reference strains T0131 and JKD6008 (Figure 2 ). The three ST764 isolates from Thailand, which share six MLST alleles in common with ST5 as well as the SCCmec type II, cluster with the S. aureus N315 isolate (Figure 2) .
Using the core genome of the ST5 isolate, S. aureus N315, as the baseline reference, the number of SNPs, including small insertions/deletions was enumerated. The core genomes of the two ST239 isolates contained a large number of common SNPs, .10 400, when compared with the core genome of S. aureus N315. There were 302 SNPs in common between all 21 ST228-MRSA-I isolates and N315 (Figure 2) . The eight ST228-MRSA-I from Switzerland contained 337 SNPs in common and the unique ST228 isolate from Spain, ARC5498, which carries the Asn 146 Lys substitution in MecA, grouped with the Swiss Characterization of ceftaroline-non-susceptible S. aureus isolates ST228 isolates (Figure 2) . A similar analysis observed 343 SNPs in common between the five and six ST228-MRSA-1 isolates that carry the Glu 239 Lys mutation from Spain and Thailand, respectively (Figure 2 ), when compared with S. aureus N315. In addition, the ST228-MRSA-I isolates could clearly be separated into two distinct subgroups. There were 446 SNPs that differentiated the core genomes of the ST228-MRSA-I isolates from Spain/Thailand (which contain the Glu 239 Lys substitution in PBP2a) from the core genomes of the ST228-MRSA-I isolates from Switzerland. Whereas many of these SNPs were randomly distributed across the core genome, there are two loci with a higher density of changes that represent transposase insertions that are distinct to each ST228 subgroup. This, taken together with the presence of discriminating polymorphisms found only in each ST228 subgroup, provides further evidence of an epidemiological linkage between the surveillance isolates from Thailand and the majority of the Spanish isolates. Further discrimination within the surveillance isolates was also possible, as there are 126 SNP differences found between the six isolates from Thailand (strain ARC3827, ARC5500 and ARC5503 with a ceftaroline MIC of 2 mg/L and ARC3828, ARC3829 and ARC3830 with a ceftaroline MIC of 8 mg/L) and the Spanish isolates with either a ceftaroline MIC of 8 mg/L (ARC3824) or a ceftaroline MIC of 2 mg/L (ARC5493, ARC5495, ARC5496 and ARC5497). There are a few additional unique SNPs that are common to the three Thailand isolates with ceftaroline MIC values of 8 mg/L that are not seen in the strains from Thailand with a ceftaroline MIC of 2 mg/L, providing supportive evidence that once the second PBP2a mutation (Glu 447 Lys) was introduced, raising the ceftaroline MIC to 8 mg/ L, there was a clonal spread rather than this mutational event occurring three separate times. Pairwise comparisons of the core genomes of the three Thailand isolates with ceftaroline MIC values of 8 mg/L showed that the number of differences range from 15 to 44, providing additional evidence of their epidemiological relatedness and supporting a clonal spread within the hospital in Thailand rather than three independent mutational events, consistent with the low frequency of resistance emergence with ceftaroline. 33 Given the confirmed evolutionary lineage of these strains determined by whole genome sequencing, as well as the ST228 Figure 2 . Similarity of the core genomes of MRSA isolates. Clustering of the core genomic sequence of MRSA isolates (1587 shared single-copy orthologues) from this study and reference genomes. The MLST designations are indicated in parentheses next to each isolate. The source location for the isolates characterized in this study (S, Spain; T, Thailand) as well as the ceftaroline MIC in mg/L (from Table 1 ) are also indicated. The number of SNPs in common between the groups of ST228-MRSA-I isolates and the N315 reference strain are indicated.
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clone being more commonly found in southern Europe and heretofore never reported in Thailand, a likely epidemiological path can be established. The most likely scenario is that an ancestral ST228-MRSA-I isolate with a ceftaroline MIC of 2 mg/L carrying the Glu 239 Lys mutation in PBP2a was transmitted to Thailand and representatives of the descendants were isolated as strains ARC3827, ARC5500 and ARC5503 in Thailand. Both the ancestral MRSA isolate in Spain (whose descendants were isolated as ARC5493, ARC5495, ARC5496 and ARC5497) and a similar isolate in Thailand then independently acquired the second mutation in PBP2a, Glu 447 Lys, which elevated the ceftaroline MIC to 8 mg/L (Figure 3) . It is also possible that a 'wild-type' ST228 S. aureus MRSA isolate was transmitted from Spain to Thailand and that the wild-type isolate in both countries independently acquired the Glu 239 Lys and the Glu 447 Lys PBP2a mutations, but given the reported low emergence of resistance after serial passage with ceftaroline, 33 this scenario seems less likely. However, it is clear that the Spanish strain ARC3824 with a ceftaroline MIC of 8 mg/ L was not the strain that was transmitted to Thailand given the distinct polymorphisms seen in this isolate compared with both the three 2 mg/L and the three 8 mg/L isolates from Thailand.
Structurally based perspective of PBP2a mutations on ceftaroline susceptibility
The residues in Table 2 were mapped onto the PBP2a structure 34, 35 bound to ceftobiprole, a closely related anti-MRSA cephalosporin that is also a potent inhibitor of PBP2a. 36 The Glu 447 Lys change is the only mutation that is located near the cephalosporin-binding pocket, while many of the remaining residues are located in the dimerization interface of the nPBD (Figure 4a ). The Glu 447 Lys mutation has also been observed as one of several mutated residues in laboratory mutants generated after serial passage with ceftobiprole. 37 While Glu 447 is not directly involved in binding based on the ceftobiprole crystal structure, it is located adjacent to the critical Tyr 446 in the binding pocket that provides a hydrophobic stack to the R2 groups of ceftobiprole (Figure 4b ). Ceftaroline and ceftobiprole have subtle differences in their R2 groups, but given that the same mutations affect susceptibility it strongly suggests that the key interacting residues and mechanisms of resistance are similar between these anti-MRSA cephalosporins. The Glu 447 Lys change is a charge alteration from negative to positive that likely creates a new salt bridge with the neighbouring Glu 460 residue. This results in a structural rearrangement of the loop and influences the flexibility to efficiently bind and accommodate large inhibitors and will impact ceftaroline susceptibility, similar to that proposed for ceftobiprole 37 ( Figure 4b ). Other mutations that result in elevated ceftaroline MIC values are all located in the nPBD. Of these, Glu 239 appears most significant and has been previously observed in ceftobiprole-resistant laboratory mutants. 37 The Glu 239 residue is located in the charged protein interface of the crystallographic dimer (Figure 4c ) and in the crystal structure it interacts with the positively charged Lys 317 and Lys 318 residues from the opposite monomer (Figure 4d ). This pattern of dimer interface interaction formed by residues with opposite charges is also observed for Glu 150 , which mutates to a Lys in previously observed S. aureus strains with ceftaroline MIC values of at least 2 mg/L 26 ( Table 2) . Mendes et al. 26 report that the ceftaroline binding affinity for PBP2a varies between isolates with nPBD mutations, but the values fall within the normal distribution seen from ceftarolinesusceptible MRSA isolates (MIC values of ≤1 mg/L) 38 and may represent normal variation between isolates and experiments with isogenic mutants would be needed to differentiate natural variability from impact in binding affinity caused by these nPBD mutations. The homodimer interface, observed in all PBP2a crystal structures, 34, 35 is likely to be replaced by another protein in physiological conditions. The consistent observation of mutations affecting drug susceptibility on this face of the protein suggests that this is the most likely interface for interaction with a functionally relevant partner(s) in the cell. This also suggests that the electrostatic surface of the partner protein is likely to be positively charged to facilitate a stable interaction. Mutation of either Glu 239 or Glu 150 to Lys results in a charge reversal that may cause repulsion and subsequent destabilization of the protein dimer interface, which appears to interfere with inhibition potency while still maintaining a critical level of functionality needed for the cells to survive.
It has been established that PBP2a-mediated resistance to b-lactams in MRSA is imparted by the weaker binding of b-lactams to the more occluded PBP2a transpeptidase pocket. 34, 35 PBP2a does not carry any transglycosylation function and hence it allows the cell to maintain peptidyltransferase function in the presence of b-lactams but relies on PBP2 for the transglycosylase activity. Experimental evidence has demonstrated a cooperative functioning between PBP2 and PBP2a (and PBP4) for S. aureus cell wall biogenesis and susceptibility to antimicrobial agents. 39, 40 However, it remains unclear if this functional synergy requires a direct protein -protein interaction or if these functions could operate independently. Expression of PBP2a in the ceftizoxime-resistant PBP2 phenotype reversed the decrease in cross-linked muropeptides, suggesting that PBP2a functions cooperatively with PBP2 targeted by the selective action Characterization of ceftaroline-non-susceptible S. aureus isolates of ceftizoxime. 39 A recent study on the inhibition of wall teichoic acid biogenesis has further supported the hypothesis that the colocalization of PBP2 and PBP2a is necessary for manifestation of the b-lactam resistance phenotype. 41 The consistently observed mutations on one face of the PBP2a nPBD in the ceftaroline-and ceftobiprole-(the only two PBP2a inhibitors) resistant isolates, along with studies highlighting the importance of close interaction with PBP2, suggest that a likely partner for PBP2a protein -protein interaction in the S. aureus cell is PBP2. Structural information on S. aureus PBP2 is available, 42 which allowed for analysis of the surface electrostatic potential. A structural overlay of PBP2 and PBP2a shows that the similar nPBD interface of PBP2 is lined with positively charged residues allowing a similar heterodimeric contact interface (Figure 4e) . Taken together, a generalized model of ceftaroline (and likely ceftobiprole) resistance mediated by PBP2a in S. aureus MRSA can be proposed. Cellular inhibition by ceftaroline can be overcome via two mechanisms. A direct change in the binding pocket conformation can result in reduced ability of the inhibitor to bind and inhibit the peptidyltransferase activity in cells. A second mechanism of inhibition is disruption of the protein -protein interaction between PBP2a and PBP2 that is needed for cooperative bridging of the transpeptidase and transglycosylase functions in PBP2a-containing MRSA strains ( Figure 5 ). This would enable an alternative protein partner, such as PBP4, with transpeptidase activity to cooperatively interact with PBP2, thus bypassing the PBP2a inhibitory roadblock caused by ceftaroline. PBP4 has been shown to not be inhibited by ceftaroline 43 but has been implicated as a PBP2 Alm et al.
partner protein that provides transpeptidase activity in S. aureus cell wall biogenesis. 41 While this second mechanism does not elevate the MIC as significantly as seen with the binding site mutation, it would influence the physiological pentapeptide function in the MRSA cell in the absence of any inhibitor. Indeed, in the wellcontrolled set of laboratory-generated ceftobiprole-resistant mutants containing nPBD mutations, the doubling times of the mutants were observed to be significantly reduced compared with the parent strains, indicating a compromised function of the mutated protein. 37 It should be noted that these nPBD mutations were found in clinical isolates prior to the launch of the anti-MRSA cephalosporins and so it is unlikely they emerged due to specific selective pressure. This raises the possibility that there is some biologically relevant functional pressure that has allowed selection and maintenance of these mutations. Further experimentation is needed to fully differentiate the impact of the nPBD mutations from the PBD mutations to understand the impact of each on cell wall biogenesis in the S. aureus cell as well as whether there is an additional mechanism of ceftaroline non-susceptibility in S. aureus.
Conclusions
MRSA isolates with ceftaroline MIC values of .2 mg/L in the 2010 surveillance set were quite rare. The characterization of the small number (n ¼ 4) of ceftaroline-resistant MRSA isolates identified (following CLSI interpretive criteria 16 ) from medical centres in Thailand and Spain has identified mutations in PBP2a that correlate with the increased ceftaroline MIC. Although additional chromosomal factors are known to influence b-lactam resistance, the potent affinity of ceftaroline for PBP2a suggests this is likely the primary mechanism of resistance and this is supported by the genomic similarity of the isolates. The PBP2a mutations identified in this study fall into two broad categories: changes that are proposed to directly influence the binding of ceftaroline to the transpeptidase domain of PBP2a; and changes in the nPBD domain that potentially destabilize a protein -protein interaction. Assimilation of evidence from this study as well as recent literature has enabled a hypothesis that the physiological partner of PBP2a in the MRSA cell is PBP2. Destabilization of the PBP2a-PBP2 interface requires that another protein, one that is recalcitrant to ceftaroline inhibition, provides the transpeptidase activity to PBP2 to ensure the correct cell wall biogenesis. Ceftaroline has low affinity for PBP4 43 and with the previously reported association of PBP4 with PBP2 make this a viable candidate worthy of additional experimentation. The use of whole genome sequencing provided a high level of discrimination between these MRSA strains and the ceftaroline-non-susceptible isolates in this study were shown to be epidemiologically related in a sublineage of ST228-MRSA-I. Furthermore, the three strains with ceftaroline MIC values of 8 mg/L isolated from the medical centre in Thailand have core genomes that are closely related enough to suggest a clonal spread. Further global epidemiological studies, especially of MRSA isolates with ceftaroline MIC values of ≥2 mg/L, are warranted to understand the transmission and emergence dynamics of ceftaroline-non-susceptible MRSA isolates.
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